Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine

References

• Allen JD, Schinkel AH. (2002). Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427–34
   PubMed Web of Science ®Google Scholar
• Allikmets R, Schriml LM, Hutchinson A, et al. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337–9
   PubMed Web of Science ®Google Scholar
• Anderson PL, Lamba J, Aquilante CL, et al. (2006). Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 42:441–9
   PubMed Web of Science ®Google Scholar
• Chen Y, Li S, Brown C, et al. (2009). Effect of genetic variation in the OCT2 on the renal elimination of metformin. Pharmacogenet Genomics 19:497–504
   PubMed Web of Science ®Google Scholar
• Choi MK, Song IS. (2012). Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm Drug Dispos 33:170–8
   PubMed Web of Science ®Google Scholar
• Doong SL, Tsai CH, Schinazi RF, et al. (1991). Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495–9
   PubMed Web of Science ®Google Scholar
• Epivir® (lamivudine) prescribing information. GlaxoSmithKline. Research Triangle Park, NC, USA, 2011
   Google Scholar
• Fukushima-Uesaka H, Maekawa K, Ozawa S, et al. (2004). Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 19:239–44
   PubMedGoogle Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–81
   PubMed Web of Science ®Google Scholar
• Heald AE, Hsyu PH, Yuen GJ, et al. (1996). Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40:1514–19
   PubMed Web of Science ®Google Scholar
• Johnson MA, Moore KH, Yuen GJ, et al. (1999). Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36:41–66
   PubMed Web of Science ®Google Scholar
• Jung N, Lehmann C, Rubbert A, et al. (2008). Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 36:1616–23
   PubMed Web of Science ®Google Scholar
• Jung N, Lehmann C, Rubbert A, et al. (2012). Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection. Available from: http://link.springer.com/article/10.1007%2Fs15010-012-0308-8 [last accessed 29 Oct 2012]
   Google Scholar
• Kang HJ, Song IS, Shin HJ, et al. (2007). Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos 35:667–75
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–51
   PubMed Web of Science ®Google Scholar
• Kurata T, Muraki Y, Mizutani H, et al. (2010). Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet 25:328–34
   PubMed Web of Science ®Google Scholar
• Minuesa G, Volk C, Molina-Arcas M, et al. (2009). Transport of lamivudine [(−)-beta-l-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252–61
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Raasch RH, et al. (1996). Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 59:550–8
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, et al. (2002). Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866–74
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S, et al. (2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227–40
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Terada T, Motohashi H, et al. (2008). Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J Hum Genet 53:607–14
   PubMed Web of Science ®Google Scholar
• Okuda M, Saito H, Urakami Y, et al. (1996). cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 224:500–7
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Connelly MC, Sun D, et al. (1999). MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048–51
   PubMed Web of Science ®Google Scholar
• Song IS, Shin HJ, Shim EJ, et al. (2008). Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 84:559–62
   PubMed Web of Science ®Google Scholar
• Soudeyns H, Yao XI, Gao Q, et al. (1991). Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 35:1386–90
   PubMed Web of Science ®Google Scholar
• Takubo T, Kato T, Kinami J, et al. (2000). Effect of lamivudine on uptake of organic cations by rat renal brush-border and basolateral membrane vesicles. J Pharm Pharmacol 52:569–75
   PubMed Web of Science ®Google Scholar
• Takubo T, Kato T, Kinami J, et al. (2002). Uptake of lamivudine by rat renal brush border membrane vesicles. J Pharm Pharmacol 54:111–17
   PubMed Web of Science ®Google Scholar
• Turriziani O, Schuetz JD, Focher F, et al. (2002). Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368:325–32
   PubMed Web of Science ®Google Scholar
• Wada S, Tsuda M, Sekine T, et al. (2000). Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 294:844–9
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, et al. (2008). OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637–45
   PubMed Web of Science ®Google Scholar
• Wijnholds J, Mol CA, van Deemter L, et al. (2000). Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97:7476–81
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Nishihara K, et al. (2005). Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70:1823–31
   PubMed Web of Science ®Google Scholar
• Zolk O, Solbach TF, König J, et al. (2009). Functional characterization of the human organic cation transporter 2 variant p.270Ala > Ser. Drug Metab Dispos 37:1312–18
   PubMed Web of Science ®Google Scholar